Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.71 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.71 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.71 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.71 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.71 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.71 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.71 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.54 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.54 |
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6903684 | 1.00 | CYP2D6 (0.71) | CYP2D6GRIN2BGRIN2DGRIN3BGRIN1 | |
| SCHEMBL6152032 | 1.00 | CYP2D6 (0.71) | CYP2D6GRIN2BGRIN2DGRIN3BGRIN1 | |
| SCHEMBL6902745 | 1.00 | CYP2D6 (0.71) | CYP2D6GRIN2BGRIN2DGRIN3BGRIN1 | |
| SCHEMBL7260277 | 1.00 | CYP2D6 (0.71) | CYP2D6GRIN2BGRIN2DGRIN3BGRIN1 | |
| SCHEMBL7332152 | 0.87 | SLC6A4 (0.56) | CYP2D6GRIN2BGRIN2DGRIN3BGRIN1 | |
| SCHEMBL7332146 | 0.87 | SLC6A4 (0.56) | CYP2D6GRIN2BGRIN2DGRIN3BGRIN1 | |
| SCHEMBL7260283 | 0.85 | CYP2D6 (0.75) | CYP2D6GRIN2BGRIN2DGRIN3BGRIN1 | |
| SCHEMBL6151424 | 0.85 | CYP2D6 (0.75) | CYP2D6GRIN2BGRIN2DGRIN3BGRIN1 | |
| SCHEMBL6152247 | 0.85 | CYP2D6 (0.75) | CYP2D6GRIN2BGRIN2DGRIN3BGRIN1 | |
| SCHEMBL6902750 | 0.85 | CYP2D6 (0.75) | CYP2D6GRIN2BGRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6806378-B2 | CATALYST SYSTEM AND A PROCESS FOR THE PREPARATION OF A NONRACEMIC CHIRAL ALCOHOL BY HYDROGENATION OF A KETONE USING THE CATALYST SYSTEM, WHEREIN THE CATALYST SYSTEM COMPRISES RUTHENIUM, A NONRACEMIC CHIRAL DIPHOSPHINE LIGAND, AN | DSM N.V. (NL) | 2004-10-19 | — | — | US | disclosed |
| EP-1465726-A1 | PROCESS FOR PREPARING NONRACEMIC CHIRAL ALCOHOLS | DSM IP Assets B.V. (NL) | 2004-10-13 | — | — | EP | disclosed |
| EP-1149831-B1 | Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol and intermediates useful therefor | PFIZER PROD INC (US) | 2004-09-01 | — | — | EP | disclosed |
| US-6743921-B2 | HYDROGENATION OF A CORRESPONDING NONRACEMIC 1-(4-BENZOXY PHENYL)-2-(4-HYDROXY-4-PHENYL-PIPERIDIN-1-YL)-1-PROPANONE USING A CATALYST SYSTEM COMPRISING RUTHENIUM, A NONRACEMIC DIPHOSPHINE LIGAND, A BIDENTATE AMINE LIGAND SELECTED FROM | DSM CATALYTICA PHARMACEUTICALS, INC. | 2004-06-01 | — | — | US | disclosed |
| US-6667317-B2 | NMDA receptor NR2B subunit antagonist and a neutrophil inhibiting factor; therapies that reduce or prevent neuronal dysfunction and death after ischemic, hypoxic or traumatic CNS insult | PFIZER INC | 2003-12-23 | — | — | US | disclosed |
| US-6667317-B2 | NMDA receptor NR2B subunit antagonist and a neutrophil inhibiting factor; therapies that reduce or prevent neuronal dysfunction and death after ischemic, hypoxic or traumatic CNS insult | PFIZER INC | 2003-12-23 | — | — | US | disclosed |
| US-20030181318-A1 | Process for preparing nonracemic chiral alcohols | DSM N.V. (NL) | 2003-09-25 | — | — | US | disclosed |
| US-20030171213-A1 | Process for preparing nonracemic chiral alcohols | DSM N.V. (NL) | 2003-09-11 | — | — | US | disclosed |
| WO-2003061824-A1 | PROCESS FOR PREPARING NONRACEMIC CHIRAL ALCOHOLS | DSM IP ASSETS B.V. (NL) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003061825-A1 | PROCESS FOR PREPARING NONRACEMIC CHIRAL ALCOHOLS | DSM IP ASSETS B.V. (NL) | 2003-07-31 | — | — | WO | disclosed |
| US-20030144521-A1 | Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl -piperidin-1-yl)-1-propanol compounds | DSM CATALYTICA PHARMACEUTICALS, INC. | 2003-07-31 | — | — | US | disclosed |
| WO-2003062180-A1 | PROCESS FOR THE PREPARATION OF NONRACEMIC SYN-1-(4-HYDROXY-PHENYL)-2-(4-HYDROXY-4-PHENYL-PIPERIDIN-1-YL)-1-PROPANOL COMPOUNDS | DSM N.V. (NL) | 2003-07-31 | — | — | WO | disclosed |
| US-6570018-B2 | Reducing the propanone of the compound with an alkali metal borohydride and cleaving the protecting group in the presence of methanesulfonic acid; n-methyl-d-aspartic acid receptor antagonist; longer shelf life | PFIZER INC | 2003-05-27 | — | — | US | disclosed |
| US-20020016466-A1 | Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol and intermediates useful therefor | PFIZER INC. | 2002-02-07 | — | — | US | disclosed |
| EP-1149831-A1 | Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol and intermediates useful therefor | Pfizer Products Inc. (US) | 2001-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016466-A1 | Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol and intermediates useful therefor | CYP4A11, CYP2S1, CYP4B1 | CYP2D6 233/4885GRIN2B 3961/4885GRIN2D 4254/4885 |
| US-20030144521-A1 | Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl -piperidin-1-yl)-1-propanol compounds | SYNJ1, HRH4, HRH3 | CYP2D6 2836/4885GRIN2B 2908/4885GRIN2D 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.